Asparkam 120 tablets

Asparkam is used in combination therapy for heart failure, ischemic heart disease, hypokalemia, and cardiac rhythm disturbances (including myocardial infarction, overdose of cardiac glycosides).

Asparkam is taken orally after meals at a dosage of 1-2 tablets three times a day. The treatment course lasts for 3-4 weeks. If necessary, the course can be repeated.

Composition per tablet
Asparkam - 500 mg
[magnesium asparaginate tetrahydrate - 177 mg
potassium asparaginate hemihydrate - 177 mg
excipients:
potato starch - 131 mg
talc - 10 mg
calcium stearate - 5 mg]

Round flat-cylindrical white tablets, with a bevel, with a score line on one side and engraved with "R" or without it on the other.

Increased sensitivity to the drug, amino acid metabolism disorders, arterial hypotension, acute and chronic renal failure, hyperkalemia, hypermagnesemia, atrioventricular conduction disorders (atrioventricular block of degrees I-III), severe myasthenia, hemolysis, adrenal cortex insufficiency, age under 18 years (efficacy and safety not established).
Use during pregnancy and breastfeeding
Use is possible if the potential benefit to the mother outweighs the possible risk to the fetus or child.
Caution is advised when prescribing during pregnancy and breastfeeding.

In cases of cardiac rhythm disturbances combined with atrioventricular block, the use of Asparkam is not recommended.

Information on the possible effects of the medicinal product on the ability to drive vehicles or operate machinery
No information available.

Possible side effects include nausea, vomiting, diarrhea, discomfort or burning sensation in the epigastric region (in patients with anacid gastritis or cholecystitis), hyperkalemia (nausea, vomiting, diarrhea, paresthesia), hypermagnesemia (facial flushing, thirst, decreased blood pressure, hyporeflexia, muscle weakness, paresis, coma, areflexia, respiratory depression, seizures).

Symptoms: conduction disturbances (especially with a history of conduction system pathology of the heart).
Treatment: intravenous administration of calcium chloride; if necessary - hemodialysis and peritoneal dialysis.

Pharmacodynamics: Concurrent use with potassium-sparing diuretics (triamterene, spironolactone), beta-adrenergic blockers, cyclosporine, heparin, angiotensin-converting enzyme inhibitors, and non-steroidal anti-inflammatory drugs increases the risk of hyperkalemia, potentially leading to arrhythmias and asystole. The use of potassium preparations together with glucocorticosteroids eliminates hypokalemia caused by the latter.

Due to the presence of potassium ions, undesirable effects of cardiac glycosides are reduced.

Due to the presence of magnesium ions, the effect of neomycin, polymyxin B, tetracycline, and streptomycin is diminished.

When used simultaneously, the preparation may enhance neuromuscular blockade caused by depolarizing muscle relaxants (atracurium besylate, decamethonium bromide, succinylcholine (chloride, bromide, iodide)).

Calcitriol increases the concentration of magnesium ions in plasma; calcium preparations reduce the effect of magnesium preparations.

Pharmacokinetics: Adsorbents and coating agents reduce the absorption of the preparation in the gastrointestinal tract.

Asparcam is a source of potassium and magnesium ions, regulates metabolic processes, helps restore electrolyte balance, and has antiarrhythmic effects.
The potassium ion is involved in both the conduction of impulses along nerve fibers and synaptic transmission, muscle contractions, and maintaining normal heart function. Disruption of potassium ion exchange leads to changes in the excitability of nerves and muscles. Active ion transport maintains a high gradient of potassium ions across the plasma membrane. At low doses, the potassium ion dilates coronary arteries; at high doses, it constricts them. It exerts negative chronotropic and bathmotropic effects; at high doses, it has negative inotropic and dromotropic effects, as well as moderate diuretic action.
The magnesium ion is a cofactor for 300 enzymatic reactions. It is an essential element in processes that ensure energy intake and expenditure. It participates in electrolyte balance, ion transport, membrane permeability, and neuromuscular excitability. It is part of the structure of (pentose phosphate) deoxyribonucleic acid. It is involved in ribonucleic acid synthesis, heredity apparatus, cell growth, and cell division processes. It limits and prevents excessive release of catecholamines during stress, and lipolysis and release of free fatty acids may occur. It acts as a "physiological" blocker of slow calcium channels. It facilitates the entry of potassium ions into cells.
Asparaginate promotes the entry of potassium and magnesium ions into the intracellular space and stimulates intercellular synthesis of phosphates.

Easily absorbed when taken orally and relatively quickly excreted in the urine.